Literature DB >> 19740706

Innate immune signals in atherosclerosis.

Anna M Lundberg1, Göran K Hansson.   

Abstract

Atherosclerosis is a chronic disease characterised by lipid retention and inflammation in the arterial intima. Innate immune mechanisms are central to atherogenesis, involving activation of pattern-recognition receptors (PRRs) and induction of inflammatory processes. In a complex tissue, such as the atherosclerotic lesion, innate signals can originate from several sources and promote atherogenesis through ligation of PRRs. The receptors recognise conserved molecular patterns on pathogens and endogenous products of tissue injury and inflammation. Activation of PRRs might affect several aspects of atherosclerosis by acting on lesion resident cells. Scavenger receptors mediate antigen uptake and clearance of lipoproteins, thereby promoting foam cell formation. Signalling receptors, such as Toll-like receptors (TLRs), lead to induction of pro-inflammatory cytokines and antigen-specific immune responses. In this review we describe the innate mechanisms present in the plaque. We focus on TLRs, their cross-talk with other PRRs, and how their signalling cascades influence inflammation within the atherosclerotic lesion. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19740706     DOI: 10.1016/j.clim.2009.07.016

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  61 in total

Review 1.  Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis.

Authors:  QiQuan Huang; Richard M Pope
Journal:  J Leukoc Biol       Date:  2010-05-19       Impact factor: 4.962

2.  Toll in the vessel wall--for better or worse?

Authors:  Göran K Hansson; Anna M Lundberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-03       Impact factor: 11.205

Review 3.  The immune system in atherosclerosis.

Authors:  Göran K Hansson; Andreas Hermansson
Journal:  Nat Immunol       Date:  2011-03       Impact factor: 25.606

Review 4.  Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases.

Authors:  Kuang-Yuh Chyu; Prediman K Shah
Journal:  Ther Adv Vaccines       Date:  2014-03

5.  Suppression of LPS-induced inflammatory responses in macrophages infected with Leishmania.

Authors:  Nicholas J Lapara; Ben L Kelly
Journal:  J Inflamm (Lond)       Date:  2010-02-02       Impact factor: 4.981

Review 6.  Arterial thrombus formation in cardiovascular disease.

Authors:  Giuseppe Lippi; Massimo Franchini; Giovanni Targher
Journal:  Nat Rev Cardiol       Date:  2011-07-05       Impact factor: 32.419

7.  Cholesterol, Inflammasomes, and Atherogenesis.

Authors:  Jose M Ordovas-Montanes; Jose M Ordovas
Journal:  Curr Cardiovasc Risk Rep       Date:  2012-02-01

Review 8.  Atherosclerosis.

Authors:  Kouji Kobiyama; Klaus Ley
Journal:  Circ Res       Date:  2018-10-26       Impact factor: 17.367

9.  Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis.

Authors:  Andreas Hermansson; Daniel F J Ketelhuth; Daniela Strodthoff; Marion Wurm; Emil M Hansson; Antonino Nicoletti; Gabrielle Paulsson-Berne; Göran K Hansson
Journal:  J Exp Med       Date:  2010-05-03       Impact factor: 14.307

Review 10.  Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors.

Authors:  Giuseppe Murdaca; Francesca Spanò; Paola Cagnati; Francesco Puppo
Journal:  Redox Rep       Date:  2013-05-10       Impact factor: 4.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.